Cardiovascular · AnticoagulantRegulatory Approvalregulatorymid-term

FDA Submission Status Update for ABANTA (Apixaban) by AZURITY

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Bristol Myers Squibb38 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/8/2026, 6:30:48 PM

Assessment confidence: 91% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's review of ABANTA (Apixaban) by AZURITY represents a significant development in the anticoagulant market, potentially intensifying competition against established products like Eliquis. Portfolio teams must evaluate how this submission could influence market dynamics and pricing strategies. Regulatory context from FDA (FDA TA — ABANTA (ORIG)) supports the near-term read. Assessment grounded in 17 ranked evidence items (17 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of ABANTA's potential approval on market dynamics and pricing strategies. The strongest clinical anchor is The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF) (ClinicalTrials.gov), sponsor/company relevance (bristol myers squibb). In Cardiovascular · Anticoagulant, 7 regulatory and 3 competitive items passed relevance filtering for Bristol Myers Squibb.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Approves Veklury as First Treatment for COVID-19. This submission indicates AZURITY's intent to enter the anticoagulant market, potentially increasing competition against established players like Bristol-Myers Squibb's Eliquis.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — ABANTA (ORIG) (FDA). Entity match (azurity); Regulatory pathway relevance (nda). The standard review process indicates a typical timeline for approval, but any delays or issues could affect market entry and competitive positioning.

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, ABANTA could capture market share from existing anticoagulants, impacting revenue for competitors and altering pricing strategies across the sector.
Upside for Bristol Myers Squibb may improve if Dose-Response to Resistance Exercise on Cardiovascular Health (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of ABANTA's potential approval on market dynamics and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any upcoming announcements regarding approval status.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — ABANTA (ORIG)
FDAhigh relevance
Entity match (azurity); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ELIQUIS (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — APREPITANT (ORIG)
FDAhigh relevance
Entity match (azurity); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SOTYKTU (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source

The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Dose-Response to Resistance Exercise on Cardiovascular Health
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)

Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
AZURITY
Eliquis

Commercial impact

medium

If approved, ABANTA could capture market share from existing anticoagulants, impacting revenue for competitors and altering pricing strategies across the sector.

Regulatory impact

medium

The standard review process indicates a typical timeline for approval, but any delays or issues could affect market entry and competitive positioning.

What to watch

Monitor the FDA's review timeline and any upcoming announcements regarding approval status.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.